Drug · DIN 02392356
ARANESP
HSA-FREE. 60 MCG/0.3 ML SINGLE-USE PREFILLED SYRINGES (SINGLEJECT)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 3, 2014; first marketed April 3, 2014.
- Drug Identification Number (DIN)
- 02392356
- Company (DIN owner)
- Amgen Canada IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Intravenous; Subcutaneous
- Therapeutic class (ATC)
- Darbepoetin alfa B03XA02
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DARBEPOETIN ALFA | 200 MCG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 24, 2012: NOC 13668Supplement to a New Drug Submission (SNDS) · New DIN
Other DINs named ARANESP
- DIN 02391740 · Marketed
- DIN 02391759 · Marketed
- DIN 02391767 · Marketed
- DIN 02391775 · Marketed
- DIN 02391783 · Marketed
- DIN 02391791 · Marketed
- DIN 02391805 · Marketed
- DIN 02391821 · Marketed
- DIN 02392313 · Marketed
- DIN 02392321 · Marketed
- DIN 02392348 · Marketed
- DIN 02392364 · Marketed
- DIN 02246353 · Approved
- DIN 02246354 · Cancelled Post Market
- DIN 02246356 · Approved
- DIN 02246359 · Approved
- DIN 02391732 · Approved
- DIN 02391813 · Approved
- DIN 02391848 · Approved